Heat and sun exposure are the main triggers for rosacea, a skin condition that affects more than 16 million Americans, mostly women. But for many sufferers, cold, dry air and wind exposure can cause flare-ups as well. This winter, there’s a new way to combat symptoms: Mirvaso, the first medication approved specifically for the facial redness associated with rosacea. (Other topical treatments target inflammatory bumps and blemishes, but not the persistent—and equally embarrassing—rosy hue.) In two clinical trials, 28 percent of patients who used Mirvaso saw their rosacea visibly reduced in as little as 30 minutes, compared to just 6 percent of patients who used a placebo.
The gel, meant for oncedaily use on the forehead, nose, chin, and cheeks, keeps redness at bay for up to 12 hours. Its…
